EFFICACY OF ADJUVANT CHEMOTHERAPY FOR ENDOMETRIAL CARCINOMA WITH HIGH-RISK FACTOR FOR RECURRENCE

Between April 1989 and December 1992, 38 patients with endometrial can cer who were at high risk for recurrence entered a prospective study d esigned to evaluate the efficacy of adjuvant platinum (cisplatin), adr iamycin (doxorubicin), and cytoxan (cyclophosphamide) (PAC) chemothera py. Patients received cisplatin (50 mg/m(2)) doxorubicin (30 mg/m(2)) and cyclophosphamide (500 mg/m(2)) at 3-week intervals for 2-3 cycles. All patients completed the treatment, there were no life-threatening adverse events. The median duration of follow-up was 52.9+/-16.9 month s. Six patients developed a recurrence, and 4 of them died after a med ian interval of 45.5 months. Five of the six patients with recurrence had stage IIIc disease. The 3-year progression-free survival was 83.3% , the overall survival rate was 89.2%. Results suggest that adjuvant c hemotherapy with PAC may reduce the incidence of recurrence and improv e the survival rate of patients with endometrial cancer.